Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | Phase 2 | withdrawn | Sep 29, 2023 | Northwestern University | PI left institution | Investigator |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | Phase 2 | withdrawn | Jun 2, 2021 | Northwestern University | Study aborted | Other (stated, no rule matched) |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 3, 2022 | National Cancer Institute (NCI) | Feasibility issues | Other (stated, no rule matched) |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | Phase 1 | terminated | Jan 3, 2019 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04645810 | A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence | N/A | withdrawn | Nov 27, 2020 | University of Rochester | study stopped early, did not enroll anyone, and will not resume | Enrollment / accrual |
| NCT05769062 | Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors | N/A | terminated | Mar 15, 2023 | Washington University School of Medicine | Former PI left the institution so enrollment was closed early. | Investigator |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to… | Phase 2 | withdrawn | Aug 1, 2022 | UNC Lineberger Comprehensive Cancer Center | Drug cannot be produced and scanner down. | Other (stated, no rule matched) |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for…(GETUGV04) | N/A | terminated | Dec 20, 2011 | Institut du Cancer de Montpellier - Val d'Aurelle | not stated | Not stated |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Phase 2 | terminated | Jun 27, 2011 | University of Southern California | Trial not progressing toward scientific goals | Other (stated, no rule matched) |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin… | Phase 1 | terminated | Apr 7, 2022 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy… | Phase 2 | terminated | Nov 5, 2020 | National Cancer Institute (NCI) | Insufficient drug supply | Drug supply |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find… | Phase 1 | terminated | Mar 11, 2022 | University of Chicago | Closed by PI due to not meeting primary endpoint | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05263492 | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent… | Phase 2 | terminated | Mar 2, 2022 | Virginia Commonwealth University | Closed early due to low enrollment rates | Enrollment / accrual |
| NCT03503097 | Genetic Testing for Men With Metastatic Prostate Cancer(GENTleMEN) | — | terminated | Apr 19, 2018 | University of Washington | Study closed to accrual before meeting enrollment goal due to end of funding. | Enrollment / accrual |
| NCT05046782 | Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With… | Phase 2 | withdrawn | Sep 16, 2021 | M.D. Anderson Cancer Center | Study withdrawn prior to full implementation due to logistical and resource-related considerations.… | Other (stated, no rule matched) |
| NCT03284346 | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer… | N/A | terminated | Sep 15, 2017 | University of Southern California | PI left | Investigator |
| NCT06527690 | Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients…(REPRESENTATION) | Phase 2 | withdrawn | Jul 30, 2024 | Latin American Cooperative Oncology Group | The study aimed to include multiple countries in Latin America, but only Brazil was feasible,… | Enrollment / accrual |
| NCT01563796 | Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer | — | terminated | Mar 27, 2012 | Medical Diagnostic Laboratories, LLC | Business decision made not to pursue malignant disease diagnostic devices | Sponsor / business decision |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06516510 | A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide… | Early Phase 1 | terminated | Jul 24, 2024 | Blue Earth Therapeutics Ltd | Based on data from the Interim Analysis, the study will not adequately inform the clinical… | Safety / toxicity |
| NCT04996849 | Contemporary Characteristics of Penile Cancer | — | terminated | Aug 9, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin… | Phase 2 / Phase 3 | terminated | May 23, 2023 | Sutro Biopharma, Inc. | Due to strategic business considerations, Sutro has deprioritized the development of luveltamab… | Safety / toxicity |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in… | Phase 1 | terminated | Jan 20, 2022 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic… | Phase 2 | suspended | Jul 6, 2022 | Emory University | Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored… | Enrollment / accrual |
| NCT02869282 | Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer(CHEMOPROST) | — | withdrawn | Aug 16, 2016 | Institut Bergonié | Principal investigator left the study center and nobody took over the study. | Investigator |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules…(Pink Orchid) | — | withdrawn | Sep 28, 2023 | AbbVie | Company Decision | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With… | Phase 1 | terminated | Feb 17, 2023 | Emory University | To review the safety data. | Safety / toxicity |
| NCT05820633 | Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate…(PCS-XI) | N/A | suspended | Apr 19, 2023 | CHU de Quebec-Universite Laval | amendment to be done, adding 200 patients | Other (stated, no rule matched) |
| NCT07117409 | Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure(RI-NIVO) | — | terminated | Aug 12, 2025 | Azienda USL Reggio Emilia - IRCCS | Healted Prematurely | Other (stated, no rule matched) |
| NCT02554565 | Innovation for Standard Identification of Insertional HPV Mutations and of Target…(PAIR HPV) | N/A | terminated | Sep 18, 2015 | Institut Curie | Study in competition with another so it was decided to stop recruitment | Enrollment / accrual |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer…(PRESERVE3) | Phase 2 | terminated | May 14, 2021 | G1 Therapeutics, Inc. | Sponsor no longer pursuing trilaciclib for the indication. | Other (stated, no rule matched) |
| NCT04053114 | MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii(MOLTHYSO) | — | withdrawn | Aug 12, 2019 | Institut Bergonié | Principal investigator left the investigational center and nobody took over. | Investigator |
| NCT04580667 | Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict… | — | withdrawn | Oct 8, 2020 | DiaCarta, Inc. | The sponsor declared bankruptcy | Other (stated, no rule matched) |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With…(ARTISTRY-7) | Phase 3 | terminated | Oct 25, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | funding withdrawn | Funding |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Phase 2 | terminated | Jun 23, 2021 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05708924 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Phase 1 | terminated | Feb 1, 2023 | Masonic Cancer Center, University of Minnesota | Product withdrawn from clinical development | Other (stated, no rule matched) |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line… | Phase 2 / Phase 3 | terminated | Mar 20, 2024 | Bio-Thera Solutions | Due to the adjustment of our company's research and development strategy, we are now prematurely… | Sponsor / business decision |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain… | Phase 2 | withdrawn | Jun 10, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03485794 | Collection of Blood in Studying Metabolites in Patients With Prostate Cancer | — | terminated | Apr 2, 2018 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With… | Phase 1 / Phase 2 | terminated | Nov 2, 2020 | Inge Marie Svane | Slow recruitment | Enrollment / accrual |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a… | Phase 2 | terminated | Apr 7, 2020 | University of Washington | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 29, 2025source: clinicaltrials